{
    "clinical_study": {
        "@rank": "6539", 
        "arm_group": {
            "arm_group_label": "Diagnostic (indocyanine green solution, isosulfan blue)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive peri-tumoral, intradermal injections of isosulfan blue and indocyanine green solution. During surgery, patients undergo identification of the sentinel lymph node and imaging using a laser with videocamera (SPY Elite camera)."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies lymph node mapping using indocyanine green solution in\n      diagnosing patients with malignant melanoma. Diagnostic procedures, such as lymph node\n      mapping using indocyanine green solution, may help find out how far the melanoma has spread\n      and may help in planning cancer treatment."
        }, 
        "brief_title": "Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma", 
        "condition": [
            "Recurrent Melanoma", 
            "Stage IA Melanoma", 
            "Stage IB Melanoma", 
            "Stage IIA Melanoma", 
            "Stage IIB Melanoma", 
            "Stage IIC Melanoma", 
            "Stage IIIA Melanoma", 
            "Stage IIIB Melanoma", 
            "Stage IIIC Melanoma", 
            "Stage IV Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To show that indocyanine green (ICG) (indocyanine green solution) is equal to both\n      isosulfan blue (ISB) and technetium Tc 99m sulfur colloid (TSC) and will allow all lymph\n      node mapping to occur in the operating room (OR).\n\n      OUTLINE:\n\n      Patients receive peri-tumoral, intradermal injections of isosulfan blue and indocyanine\n      green solution. During surgery, patients undergo identification of the sentinel lymph node\n      and imaging using a laser with videocamera (SPY Elite camera)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to understand and willingness to sign informed consent document\n\n          -  Signed written informed consent\n\n          -  Patients with malignant melanoma (MM) undergoing sentinel lymph node biopsy (SNLB)\n\n          -  Complete blood count (CBC) and metabolic panel within 6 months\n\n        Exclusion Criteria:\n\n          -  History of hepatic or renal failure\n\n          -  Allergy to iodine containing products\n\n          -  Patients who are pregnant or may be pregnant\n\n          -  Patients with psychiatric or addictive disorders that in the opinion of the research\n             team, may not be able to meet study requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898403", 
            "org_study_id": "MEL0010", 
            "secondary_id": [
                "NCI-2013-01286", 
                "27319", 
                "P30CA124435"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (indocyanine green solution, isosulfan blue)", 
                "description": "Given peri-tumoral and intradermally", 
                "intervention_name": "indocyanine green solution", 
                "intervention_type": "Drug", 
                "other_name": [
                    "IC-GREEN", 
                    "ICG solution"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (indocyanine green solution, isosulfan blue)", 
                "description": "Given peri-tumoral and intradermally", 
                "intervention_name": "isosulfan blue", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Lymphazurin", 
                    "N-[4-[4-(diethylamino)phenyl] (2,5-disulfophenyl) Methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium hydroxide"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (indocyanine green solution, isosulfan blue)", 
                "description": "Undergo lymph node mapping", 
                "intervention_name": "lymph node mapping", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Diagnostic (indocyanine green solution, isosulfan blue)", 
                "description": "Undergo SNLB", 
                "intervention_name": "sentinel lymph node biopsy", 
                "intervention_type": "Procedure", 
                "other_name": "sentinel node biopsy"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 15, 2014", 
        "location": {
            "contact": {
                "email": "grecors@stanford.edu", 
                "last_name": "Ralph S. Greco", 
                "phone": "650-736-1355"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University Hospitals and Clinics"
            }, 
            "investigator": {
                "last_name": "Ralph S. Greco", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Testing the Efficacy of Indocyanine Green Imaging ( ICG-SPY ) in the Identification of Sentinel Lymph Nodes ( SLN ) in Patients With Malignant Melanoma", 
        "overall_official": {
            "affiliation": "Stanford University Hospitals and Clinics", 
            "last_name": "Ralph Greco", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "SLN will be identified and mapped using indocyanine green solution, isosulfan blue, and TSC. Participants will undergo peri-tumoral, intradermal injection of ISB AND ICG, in addition intra-operatively the SPY camera will be ued to identify SLN and take images.", 
            "measure": "Mapping of the Sentinel Lymph Nodes (SLN)", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898403"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}